Valneva Toekomstige groei

Future criteriumcontroles 5/6

Valneva zal naar verwachting groeien in winst en omzet met respectievelijk 4.6% en 24.6% per jaar. De winst per aandeel zal naar verwachting groeien met 17.6% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -27.7% zijn.

Belangrijke informatie

4.6%

Groei van de winst

17.6%

Groei van de winst per aandeel

Biotechs winstgroei	28.3%
Inkomstengroei	24.6%
Toekomstig rendement op eigen vermogen	-27.7%
Dekking van analisten	Good
Laatst bijgewerkt	19 Nov 2024

Recente toekomstige groei-updates

Recent updates

Winst- en omzetgroeiprognoses

NasdaqGS:VALN - Toekomstschattingen van analisten en financiële gegevens uit het verleden (EUR Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	285	-39	-1	-4	8
12/31/2025	213	-67	-57	-50	9
12/31/2024	170	10	40	44	7
9/30/2024	159	-7	-169	-143	N/A
6/30/2024	156	-32	-215	-204	N/A
3/31/2024	153	-24	-222	-207	N/A
12/31/2023	154	-101	-217	-203	N/A
9/30/2023	223	-113	-208	-193	N/A
6/30/2023	426	-7	-231	-211	N/A
3/31/2023	373	-135	-267	-243	N/A
12/31/2022	361	-143	-275	-245	N/A
9/30/2022	439	73	-195	-149	N/A
6/30/2022	304	-159	-177	-108	N/A
3/31/2022	347	-72	-83	2	N/A
12/31/2021	348	-73	-16	77	N/A
9/30/2021	121	-248	15	97	N/A
6/30/2021	110	-125	51	109	N/A
3/31/2021	98	-91	147	182	N/A
12/31/2020	110	-64	118	138	N/A
9/30/2020	104	-62	67	78	N/A
6/30/2020	120	-25	97	105	N/A
3/31/2020	127	-8	-7	3	N/A
12/31/2019	126	-2	-5	6	N/A
9/30/2019	116	4	0	10	N/A
6/30/2019	109	1	10	16	N/A
3/31/2019	116	7	14	17	N/A
12/31/2018	113	3	13	16	N/A
9/30/2018	107	-7	4	6	N/A
6/30/2018	110	-7	N/A	10	N/A
3/31/2018	108	-8	N/A	5	N/A
12/31/2017	105	-11	N/A	13	N/A
9/30/2017	103	-11	N/A	17	N/A
6/30/2017	100	-14	N/A	19	N/A
3/31/2017	102	-46	N/A	25	N/A
12/31/2016	98	-49	N/A	7	N/A
9/30/2016	93	-63	N/A	4	N/A
6/30/2016	96	-61	N/A	-5	N/A
3/31/2016	89	-35	N/A	-17	N/A
12/31/2015	83	-21	N/A	-20	N/A
9/30/2015	74	-16	N/A	-24	N/A
6/30/2015	65	-13	N/A	-19	N/A
3/31/2015	55	-9	N/A	-15	N/A
12/31/2014	42	-26	N/A	-15	N/A
9/30/2014	41	-21	N/A	-6	N/A
6/30/2014	43	-28	N/A	-21	N/A
3/31/2014	41	-29	N/A	-27	N/A
12/31/2013	36	-24	N/A	-21	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er wordt voorspeld dat VALN de komende 3 jaar winstgevend zal worden, wat wordt beschouwd als een snellere groei dan de spaarquote ( 2.6% ).

Winst versus markt: Er wordt verwacht dat VALN de komende 3 jaar winstgevend zal worden. Dit wordt gezien als een groei die boven het gemiddelde van de markt ligt.

Hoge groeiwinsten: Er wordt verwacht dat VALN binnen 3 jaar winstgevend zal worden.

Omzet versus markt: De omzet van VALN ( 24.6% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van VALN ( 24.6% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat VALN binnen 3 jaar verliesgevend zal zijn.

Valneva Toekomstige groei

Future criteriumcontroles 5/6

Belangrijke informatie

Recente toekomstige groei-updates

Valneva SE Confirms Earnings Guidance for the Fiscal Year 2024

Valneva Se Announces Earnings Guidance for 2024

Valneva SE Revises Earnings Guidance for the Full Year 2023

Valneva SE Revises Earnings Guidance for the Full Year 2023

Valneva Se Provides Revenue Guidance for the Year 2023

Valneva SE Provides Financial Guidance of 2023

Recent updates

Valneva and LimmaTech Announces First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2

Valneva SE to Report Q1, 2025 Results on May 07, 2025

Valneva SE and LimmaTech Biologics AG Receives FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4V

Valneva SE and Pfizer Inc. Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate

Valneva SE Receives Marketing Authorization in Europe for the World's First Chikungunya Vaccine, Ixchiq

Valneva SE Appoints Daniele Guyot-Caparros as Board of Directors

Valneva SE Confirms Earnings Guidance for the Fiscal Year 2024

Valneva SE Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate

U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ

Valneva Se Announces Earnings Guidance for 2024

Valneva Se Announces the First Participant Has Been Vaccinated in the Phase 2 Clinical Trial Evaluating the Safety and Immunogenicity in Children of Two Different Dose Levels of Valneva’S Single-Shot Chikungunya Vaccine

Valneva SE to Report Fiscal Year 2023 Results on Mar 21, 2024

Valneva SE Revises Earnings Guidance for the Full Year 2023

Valneva SE Revises Earnings Guidance for the Full Year 2023

Valneva SE to Report Q1, 2024 Results on May 07, 2024

Valneva SE reported positive antibody persistence data twenty-four months after vaccination with a single dose of its chikungunya vaccine IXCHIQ®

Ema Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment

Ema Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment

Valneva SE Announces Board Changes

Valneva SE Announces U.S. FDA Approval of World's First Chikungunya Vaccine, IXCHIQ(R)

Valneva Se Provides Revenue Guidance for the Year 2023

Valneva SE Announces Positive Pediatric and Adolescent Immunogenicity and Safety Data for Their Lyme Disease Vaccine Candidate, VLA15

Health Canada Accepts Valneva's Chikungunya Vaccine License Application for Review

Valneva SE Reports Positive Initial Phase 3 Safety Data in Adolescents for Its Single-Shot Chikungunya Vaccine Candidate Vla1553

Valneva SE announced a financing transaction

Valneva Se Appoints Kathrin U Jansen to Supervisory Board

Valneva SE Announces Publication of its Chikungunya Vaccine Candidate Phase 3 Data in the Lancet

Valneva SE Provides Financial Guidance of 2023

Pfizer Inc. and Valneva SE Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15

Valneva Completes Enrollment for Adolescent Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate

Valneva SE to Report First Half, 2023 Results on Aug 10, 2023

Valneva SE Reports Further Heterologous Booster Data from Exploratory, Small Clinical Study for its Inactivated COVID-19 Vaccine, VLA2001

Valneva Completes BLA Submission to U.S. FDA for Its Single-Shot Chikungunya Vaccine Candidate

Valneva SE to Report Q1, 2023 Results on May 04, 2023

Valneva Reports Positive 12-Month Antibody Persistence Data for Single-Shot Chikungunya Vaccine Candidate

Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults for Lyme Disease Vaccine Candidate

ValnevaSE Appoints Dipal Patel as Chief Commercial Officer

Valneva SE Reiterates Earnings Guidance for the Fiscal 2022

Valneva to Present on Its Single-Shot Chikungunya Vaccine Candidate At Leading Scientific Conferences

Valneva SE announced a financing transaction

Valneva seeking a partnership for next-gen COVID-19 vaccine

Valneva Reports Further Positive Phase 3 Immunogenicity and the First Heterologous Booster Results for its Inactivated, Adjuvanted COVID-19 Vaccine VLA2001

Valneva shows booster effect of COVID shot against AstraZeneca vaccine

Valneva SE Confirms World Health Organization Recommendations for its Inactivated COVID-19 Vaccine

Valneva SE Initiates Rolling Submission of U.S. Food and Drug Administration Biologics License Application for Its Single Shot Chikungunya Vaccine Candidate

Valneva launches up to $75M at-the-market ADS offering program

Valneva SE Provides Revenue Guidance for the Fiscal Year 2022

Pfizer Inc. and Valneva SE Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15

Valneva: Vaccine Business, Catalysts Ahead, And Pfizer's Lyme Love

Valneva agrees to cut COVID vaccine supplies to EU

Valneva Announces Initiation of the Phase 3 Study of Lyme Disease Vaccine

Valneva SE Announces Supervisory Board Member Appointments

Valneva SE announced that it expects to receive €90.627232 million in funding from Pfizer Inc.

Valneva SE announced that it expects to receive €90.627232 million in funding from Pfizer Inc.

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven